Westminster, CA – October 6, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it signed a channel partnership agreement with Product Recovery Management, Inc. to sell and distribute BioLargo’s water treatment systems and act as a contract manufacturer.

Product Recovery Management (PRM) (https://www.prmfiltration.com/), based out of Butner, NC, is a UL-certified equipment integrator specializing in remediation services with over 40 years of history serving customers. PRM designs and manufactures treatment systems that address a wide variety of contamination challenges in the remediation and landfill industries, including PFAS contamination. Their Butner operations include a 250,000 square foot manufacturing facility with large-scale fabrication capabilities.

The channel partner agreement grants PRM a license to sell and distribute BioLargo’s innovative water and wastewater treatment technologies, including but not limited to the Aqueous Electrostatic Concentrator (AEC), BioLargo’s effective, affordable, low-waste solution for removing per- and polyfluoroalkyl substances (PFAS) from water. PRM will also be authorized to sell BioLargo’s Advanced Oxidation System (AOS) technology, the energy-efficient and affordable solution for simultaneous water disinfection and micropollutant treatment.

PRM will also be a contract manufacturer for BioLargo’s water treatment technologies, including the AEC, the AOS, as well as other treatment systems designed by BioLargo (e.g., reverse osmosis systems).

“PRM has substantial expertise and infrastructure to support the roll-out and manufacturing of our cleantech systems. This relationship will allow us to more readily meet the growing demand for our systems and expand our reach into the market. We have already begun scoping our first project together,” says Randall Moore, President of BioLargo Engineering, Science & Technologies (BioLargo’s engineering subsidiary – www.BioLargoEngineering.com).

“BioLargo’s AEC and AOS technologies are unique and valuable tools for targeted removal of tough-to-treat water contaminants including PFAS and micropollutants, both of which currently lack effective and affordable options in the marketplace. We recognized in BioLargo a commitment to serve customers with technical excellence and reliable results. We look forward to working with the BioLargo team,” said Robert Phillips, Jr., President of Product Recovery Management.

About PRM:

Headquartered in Butner, NC. PRM was founded in 1990 by Mel and Brian Phillips. Originating as Phillips Electric Company in 1976, PRM is now a premier environmental remediation and landfill gas company with systems operating across the globe. PRM is an Original Equipment Manufacturer (OEM) of pollution control and other equipment, mainly focused on the Remediation and Landfill Industries. Their experiences and talents are well diversified.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo’s Aqueous Electrostatic Concentrator, the company’s treatment solution to effectively and affordably remove per- and polyfluoroalkyl substances from water, has been featured in a prominent water treatment industry publication, Treatment Plant Operator (TPO).

The article, which features an interview with BioLargo CEO Dennis Calvert and Director of Strategic Marketing and Business Development Tonya Chandler, does a deep dive on why the AEC is set to disrupt the PFAS treatment market.

Download your copy of the article here:

TPO0222 Technology Deep Dive

Westminster, CA – December 23, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its Aqueous Electrostatic Concentrator (AEC) has been proven to eliminate multiple per- and polyfluoroalkyl substance (PFAS) compounds from water provided by a large municipality in Southern California.

Found in water all over the world, PFAS are a group of chemicals generated by industrial operations that have been linked to adverse health effects. They are subject to escalating regulatory action by the Biden Administration and the EPA due to their inability to break down naturally in the environment and their impacts on human health. Also known as “forever chemicals”, PFAS have been linked to cancer, developmental delays, hormone disorders, and more. According to Washington DC based Environmental Working Group, PFAS has been founding in water in over 2,800 locations in the United States.

Previously, the company reported that the AEC had been shown to reduce the levels of several PFAS compounds present in water provided by the prospective municipal client to below State and Federal standards. These new results prove that the AEC has removed multiple PFAS compounds to below the limit of quantification (i.e., functionally eliminated) following optimization of the AEC’s membranes and contact time.

Randall Moore, President of BioLargo Engineering, Science & Technologies commented, “These results confirm not only that the AEC can deliver virtually total elimination of PFAS from contaminated drinking water, but that the technology can, with relative ease, be fine-tuned to achieve varying levels of treatment performance as prescribed by a client’s own treatment goals and regulatory needs.”

Tonya Chandler, Director of Strategic Marketing and Business Development at BioLargo, commented, “These results show that the AEC is an effective solution for customers seeking PFAS water treatment and removal, and will be integral as we advance to commercial trials and first sales of the technology. Our AEC system is capable of total PFAS elimination while generating less than 1/1000 the volume of PFAS-laden waste product compared to carbon filtration, the most common solution in the market today. No one wants to trade one environmental disaster for another, and the AEC helps avoid the trailing environmental impact and significant cost associated with disposal of PFAS-laden carbon.”

To learn more about BioLargo’s AEC technology, visit https://www.biolargoengineering.com/biolargo-aec/.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Westminster, CA – December 8, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, has taken the next step to commercialize the new wastewater treatment technology, called a “minimal liquid discharge” system, that it designed and manufactured for Garratt-Callahan, a century-old national water treatment company. In this stage, BioLargo engineers will process contaminated water with a full-scale prototype of the new technology to verify its treatment efficacy and durability. Once this stage is completed successfully, sales can begin to Garratt-Callahan customers.

The new wastewater treatment system is based on Garratt-Callahan’s “minimal liquid discharge (MLD)” technology, which reduces the volume of wastewater discharge from industrial facilities, saving customers disposal fees while reducing strain on sewage infrastructure and the environment. The engineers will start by treating simulated industrial wastewater to optimize the technology’s performance, then will finish by treating actual industrial wastewater provided by Garratt-Callahan customers.

“We are excited to be working with Garratt-Callahan to launch this product because of their pedigree of innovation and integrity in the water industry. Their focus on developing technologies that reduce freshwater usage aligns with our values of focusing on sustainable solutions above all else,” said Randall Moore, President of BioLargo Engineering, Science & Technologies.

Tonya Chandler, BioLargo’s Director of Strategic Marketing and Business Development, said, “This project highlights our capabilities to serve customers as an innovator and solutions provider in wastewater treatment. We helped scale the design of the MLD system, we manufactured it, and now we’re testing it in our in-house water lab to validate its performance before it ships to customers.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Over the past year, the Biden Administration and the Environmental Protection Agency have begun the process of regulating per- and polyfluoroalkyl substances (PFAS) in drinking water and creating new rules on discharge of PFAS chemicals from industrial facilities. On October 18, the EPA and the White House both made major announcements of plans to reduce the impact of these toxic chemicals, providing greater clarity on the evolving regulatory landscape surrounding PFAS over the coming years.

First, the EPA announced their “PFAS Strategic Roadmap” this week, outlining the agency’s multifaceted strategy to regulate and remediate PFAS throughout over the next three years and beyond. The roadmap, found here, describes the anticipated timeline for various aspects of regulatory action on PFAS chemicals. The EPA intends to release more details about each aspect of their roadmap in a series of webinars planned over the next few weeks.

Some of the highlights of the EPA’s roadmap include:

• Nationwide monitoring of PFAS in drinking water, aimed for the Fall of 2021.
• A proposal to designate certain PFAS chemicals as hazardous chemicals under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA; a.k.a. the “Superfund”), which will provide federal funding for cleanup of PFAS-contaminated sites and increase the handling requirements for PFAS-contaminated materials.
• The establishment of national drinking water regulations for two of the most common PFAS chemicals, PFOA and PFOS, that would set “enforceable limits” and necessitate that all public water supplies be monitored. This rulemaking is targeted for Fall of 2022, with a final rule made Fall of 2023.
• Develop rules surrounding monitoring of PFAS-containing emissions from industrial facilities (aimed for Fall of 2022).
• Plans to review new and existing PFAS chemicals under the Toxic Substances Control Act
• Evaluate and assist in the development of new technologies that can help remove PFAS from the environment, including site cleanup and remediation technologies and water treatment technologies.

The same day as the EPA’s roadmap was released, the Biden-Harris Administration announced their formal plan to combat PFAS contamination across the country. In their press release, they promised “accelerated efforts to protect Americans from per- and polyfluoroalkyl substances (PFAS)” through a concerted effort by eight federal agencies to mitigate PFAS from different angles.

The first and most wide-reaching part of their plan is the EPA’s new PFAS roadmap, detailed above. The Department of Defense is another agency taking swift and concrete action. The DOD is responsible for more than 700 potentially PFAS-contaminated sites around the country such as air force bases and National Guard locations where PFAS-containing fire-fighting foam was used. The DOD is presently conducting cleanup assessments to plan for the remediation of all sites where PFAS contamination is found. The agency is also funding over $150 million to help develop PFAS remediation solutions.

Other federal agencies who will be taking action as part of the federal government’s PFAS response include the Food and Drug Administration, the Department of Agriculture, the Department of Homeland Security, the Department of Health and Human Services, the Federal Aviation Administration, and the White House’s Council on Environmental Quality (CEQ). These agencies are engaged in initiatives ranging from funding scientific research on the health effects of the broader range of PFAS chemicals, to programs to support first responders affected by PFAS-related health problems, to efforts to quantify and mitigate the presence of PFAS in food products and livestock animals.

This week’s announcements bring much-awaited clarity about the Federal government’s plans to create a regulatory framework surrounding PFAS. Municipal governments, water agencies, and industrial companies need that clarity in order to make informed decisions on what treatment and mitigation systems they should implement to safeguard their water or wastewater into the future. The EPA’s new roadmap doesn’t provide all the answers to questions about the evolving regulatory landscape, but it does give industry stakeholders a solid idea of when different regulatory actions are likely to happen, and what their impact might be.

In particular, the decision to move ahead with designating certain PFAS as hazardous chemicals under CERCLA is likely to have substantial effects on the way PFAS-contaminated site and waterways are remediated. Making PFAS-contaminated sites eligible for Superfund funding may accelerate the pace of treating those sites, especially in light of the high capital cost of some PFAS cleanup projects. The CERCLA proposal may also make handling PFAS-laden waste, such as that waste generated by PFAS water treatment, a more complex issue, which will probably encourage customers to choose PFAS treatment options that generate less waste.

About BioLargo’s PFAS Treatment Technology

BioLargo’s PFAS water treatment technology was developed from the ground-up to be the sustainable, low-waste solution for affordable PFAS removal. Called the Aqueous Electrostatic Concentrator (AEC), it works by separating PFAS compounds in an electric field and forcing them onto specialized, compact, proprietary membranes, which can later be disposed of easily and safely.

The AEC removes more than 99% of PFAS from water in continuous flow, at energy costs as low as 30 cents per 1,000 gallons.

Compared to carbon-based filtration, the most common PFAS removal system, the AEC generates approximately 1/1000 the amount of PFAS-laden waste by weight, has a significantly lower carbon footprint, produces higher purity water, and is more compact. With regulations around the U.S. tightening surrounding the handling of PFAS-laden waste, this makes the AEC a more practical solution for PFAS water treatment.

You can learn more about the BioLargo AEC, as well as BioLargo’s PFAS water testing program, at www.biolargoengineering.com/biolargo-aec.